0001104659-21-150527.txt : 20211216 0001104659-21-150527.hdr.sgml : 20211216 20211216161622 ACCESSION NUMBER: 0001104659-21-150527 CONFORMED SUBMISSION TYPE: 4/A PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20211213 FILED AS OF DATE: 20211216 DATE AS OF CHANGE: 20211216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Rombotis Spiro George CENTRAL INDEX KEY: 0001357396 FILING VALUES: FORM TYPE: 4/A SEC ACT: 1934 Act SEC FILE NUMBER: 000-50626 FILM NUMBER: 211497965 MAIL ADDRESS: STREET 1: C/O CYCLACEL PHARMACEUTICALS, INC. STREET 2: 200 CONNELL DRIVE, SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 FORMER NAME: FORMER CONFORMED NAME: Rombotis Spiro DATE OF NAME CHANGE: 20060324 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Cyclacel Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001130166 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 911766850 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 BUSINESS PHONE: 908-517-7330 MAIL ADDRESS: STREET 1: 200 CONNELL DRIVE STREET 2: SUITE 1500 CITY: BERKELEY HEIGHTS STATE: NJ ZIP: 07922 FORMER COMPANY: FORMER CONFORMED NAME: XCYTE THERAPIES INC DATE OF NAME CHANGE: 20001218 4/A 1 tm2135616d1_4a.xml OWNERSHIP DOCUMENT X0306 4/A 2021-12-13 2021-12-15 0 0001130166 Cyclacel Pharmaceuticals, Inc. CYCC 0001357396 Rombotis Spiro George C/O CYCLACEL PHARMACEUTICALS, INC., 200 CONNELL DRIVE, SUITE 1500 BERKELEY HEIGHTS NJ 07922 1 1 0 0 President and CEO Stock Option (right to buy) 3.45 2021-12-13 4 A 0 190000 0 A 2031-12-13 Common Stock 190000 190000 D These securities are exercisable over a three-year period, with 1/36 of the options granted vesting on a monthly basis. These securities were granted as part of the Issuer's annual compensation review to executive officers. This Form 4 is being amended to correct a typographical error in the number of shares of Common Stock underlying the options granted to the reporting person on December 13, 2021. 190,000 shares of Common Stock underlie the granted options. /s/ Spiro Rombotis 2021-12-16